These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Prognostic value of plasma-cell immunophenotype in patients with multiple myeloma. Sakalová A; Holománová D; Mikulecký M; Mistrík M; Lipsic T; Steruská M Neoplasma; 1993; 40(6):351-4. PubMed ID: 8289966 [TBL] [Abstract][Full Text] [Related]
6. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol]. Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962 [TBL] [Abstract][Full Text] [Related]
7. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039 [TBL] [Abstract][Full Text] [Related]
8. Treatment of multiple myeloma with an intensive 5-drug combination or intermittent melphalan and prednisone; a randomised multicentre trial. Finnish Leukaemia Group. Palva IP; Ahrenberg P; Ala-Harja K; Almqvist A; Apajalahti J; Hallman H; Hänninen A; Ilvonen M; Isomaa B; Järvenpää E Eur J Haematol; 1987 Jan; 38(1):50-4. PubMed ID: 3582605 [TBL] [Abstract][Full Text] [Related]
9. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486. Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521 [TBL] [Abstract][Full Text] [Related]
10. Intensive chemotherapy with combinations containing anthracyclines for refractory and relapsing multiple myeloma. Finnish Leukaemia Group. Palva IP; Ahrenberg P; Ala Harja K; Almqvist A; Elonen E; Hallman H; Hänninen A; Ilvonen M; Isomaa B; Jouppila J Eur J Haematol; 1990 Feb; 44(2):121-4. PubMed ID: 2180741 [TBL] [Abstract][Full Text] [Related]
11. Alternating combination chemotherapy does not delay development of refractoriness in myeloma. Osby E; Beksac M; Reizenstein P Anticancer Res; 1986; 6(5):1145-7. PubMed ID: 3800322 [TBL] [Abstract][Full Text] [Related]
12. [Therapy of multiple myeloma. Results of sequential treatment with melphalan-prednisolone and the M2 protocol]. Steinke B; Busch FW; Stapelfeld S; Ostendorf P; Waller HD Dtsch Med Wochenschr; 1984 Jun; 109(26):1015-9. PubMed ID: 6547386 [TBL] [Abstract][Full Text] [Related]
13. Clinical evaluation of response or escape to chemotherapy and of survival of patients with multiple myeloma. A prospective study of 202 patients (1975-1982). Bataille R; Souteyrand P; Sany J Anticancer Res; 1984; 4(6):339-45. PubMed ID: 6517530 [TBL] [Abstract][Full Text] [Related]
14. [Combination chemotherapy with vincristine, melphalan, CCNA, cyclophosphamide, prednisone in myeloma]. Le Loët X; Monconduit M; Menard JF; Deshayes P; Grobois B; Tanguy A; Prevost E; Piguet H Rev Rhum Mal Osteoartic; 1984 May; 51(5):263-7. PubMed ID: 6740189 [TBL] [Abstract][Full Text] [Related]
15. Treatment of multiple myeloma in old patients. Finnish Leukaemia Group. Palva IP; Ahrenberg P; Ala-Harja K; Almqvist A; Hänninen A; Ilvonen M; Isomaa B; Jouppila J; Järvenpää E; Kilpi H Eur J Haematol; 1989 Oct; 43(4):328-31. PubMed ID: 2583258 [TBL] [Abstract][Full Text] [Related]
16. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma. Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803 [TBL] [Abstract][Full Text] [Related]
17. Comparison of two combination chemotherapy regimens for multiple myeloma: methyl-CCNU, cyclophosphamide, and prednisone versus melphalan and prednisone. Cavagnaro F; Lein JM; Pavlovsky S; Becherini JO; Pileggi JE; Micheo EQ; Jait C; Musso A; Suárez A; Pizzolato M Cancer Treat Rep; 1980 Jan; 64(1):73-9. PubMed ID: 6991106 [TBL] [Abstract][Full Text] [Related]
18. Nitrosoureas in multiple myeloma. Salmon SE Cancer Treat Rep; 1976 Jun; 60(6):789-94. PubMed ID: 782701 [TBL] [Abstract][Full Text] [Related]
19. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study. Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S; Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805 [TBL] [Abstract][Full Text] [Related]
20. IgD multiple myeloma. A report of three cases. Martini R; Santini S; Bottari G Minerva Med; 1996 Mar; 87(3):109-12. PubMed ID: 8668286 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]